Skip to search formSkip to main contentSkip to account menu

3 ML idursulfase 2 MG/ML Injection [Elaprase]

Known as: 3 ML Elaprase 2 MG/ML Injection, IDURSULFASE 6 mg in 3 mL INTRAVENOUS SOLUTION, CONCENTRATE [ELAPRASE], elaprase 6 MG in 3 ML Injection 
National Institutes of Health

Related topics

Related topics

6 relations
ElapraseInjectionPolysorbate 20Sodium Chloride

Broader (1)

idursulfase Injection [Elaprase]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Zehn Jahre „Hunter Outcome Survey“
Mucopolysaccharidose Typ II (MPS II, Hunter Syndrom; OMIM 309900) ist eine seltene lysosomale Speicherkrankheit mit progressiven… 
2015
2015
A RARE CASE OF HUNTER SYNDROME – CASE REPORT
Mucopolysaccharidoses (MPSs) are a group of rare genetic disorders within the larger family of lysosomal diseases. MPSs disorders… 
2014
2014
Impact of Enzyme Replacement Therapy on Linear Growth in Korean Patients with Mucopolysaccharidosis Type II (Hunter Syndrome)
Hunter syndrome (or mucopolysaccharidosis type II [MPS II]) arises because of a deficiency in the lysosomal enzyme iduronate-2… 
2011
2011
Neonatal pulmonary interstitial glycogenosis in a patient with Hunter syndrome
In 2004, we reported on a neonate with pulmonary interstitial glycogenosis (PIG), with favorable outcome at the age of 19 months… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)